Search
Axitinib
go.drugbank.com/drugs/DB06626ApprovedInvestigationalIt is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative. … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: INLYTA (TABLETS 5 MG), Axitinib STADA 5 mg FilmtablettenVilazodone
go.drugbank.com/drugs/DB06684ApprovedInvestigationalVilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin 5-HT1 Receptor AgonistsProducts: ZİLADONE 10 MG FİLM KAPLI TABLET, 30 ADET, ZİLADONE 20 MG FİLM KAPLI TABLET, 30 ADETTranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalA propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and p...
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 CYP1A2 InhibitorsProducts: Tranylcypromin Aristo 10 mg Filmtabletten, Tranylcypromin Aristo 20 mg FilmtablettenNonoxynol-9
go.drugbank.com/drugs/DB06804ApprovedWithdrawnIn several European countries, spermicides are no longer on the market. … N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams and condom lubricants.
Products: OKSİNOL 150 MG OVÜLAcemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigational[A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E. … Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and
Products: RANTUDİL 90 MG UZATILMIŞ SALIMLI KAPSÜL, 10 ADET, RANTUDIL FORTE 60 MG KAPSUL, 30 ADETLanadelumab
go.drugbank.com/drugs/DB14597ApprovedInvestigational[A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.
Products: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADETBenperidol
go.drugbank.com/drugs/DB12867ApprovedWithdrawnBenperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.
Products: BENPERIDOL-NEURAX 10 MG, BENPERIDOL-NEURAX 2 MGRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260187,A260192,A260197] Approximately 80% of myasthenia gravis patients tested positive for the AChR autoantibodies, and 40% of these AChR-negative or seronegative patients were found to have MuSK autoantibodies
Products: Rystiggo 280 mg/2 ml Enjeksiyonluk Çözelti, 1 adetInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalBy binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol. … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Products: LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML, LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETBenralizumab
go.drugbank.com/drugs/DB12023ApprovedInvestigationalBenralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils … [A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019]
Categories: Interleukin-5 Receptor alpha-directed Cytolytic Antibody, Interleukin 5 Receptor alpha-directed Antibody InteractionsProducts: Fasenra 30 mg solution for injection in pre-filled syringe, FASENRA 30 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR